annual cash & cash equivalents:
$69.33M-$5.72M(-7.63%)Summary
- As of today (May 29, 2025), SUPN annual cash & cash equivalents is $69.33 million, with the most recent change of -$5.72 million (-7.63%) on December 31, 2024.
- During the last 3 years, SUPN annual cash & cash equivalents has fallen by -$134.10 million (-65.92%).
- SUPN annual cash & cash equivalents is now -75.98% below its all-time high of $288.64 million, reached on December 31, 2020.
Performance
SUPN Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$115.85M+$46.52M(+67.09%)Summary
- As of today (May 29, 2025), SUPN quarterly cash & cash equivalents is $115.85 million, with the most recent change of +$46.52 million (+67.09%) on March 31, 2025.
- Over the past year, SUPN quarterly cash & cash equivalents has increased by +$52.45 million (+82.72%).
- SUPN quarterly cash & cash equivalents is now -73.92% below its all-time high of $444.14 million, reached on March 31, 2018.
Performance
SUPN quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SUPN Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.6% | +82.7% |
| 3 y3 years | -65.9% | +0.1% |
| 5 y5 years | -61.8% | -48.7% |
SUPN Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -65.9% | at low | -33.2% | +368.9% |
| 5 y | 5-year | -76.0% | at low | -59.9% | +368.9% |
| alltime | all time | -76.0% | +192.0% | -73.9% | +869.0% |
SUPN Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $115.85M(+67.1%) |
| Dec 2024 | $69.33M(-7.6%) | $69.33M(+118.9%) |
| Sep 2024 | - | $31.67M(-39.2%) |
| Jun 2024 | - | $52.09M(-17.8%) |
| Mar 2024 | - | $63.40M(-15.5%) |
| Dec 2023 | $75.05M(-19.4%) | $75.05M(-21.0%) |
| Sep 2023 | - | $94.98M(+284.5%) |
| Jun 2023 | - | $24.71M(-57.7%) |
| Mar 2023 | - | $58.44M(-37.2%) |
| Dec 2022 | $93.12M(-54.2%) | $93.12M(-16.5%) |
| Sep 2022 | - | $111.49M(-35.7%) |
| Jun 2022 | - | $173.43M(+49.9%) |
| Mar 2022 | - | $115.72M(-43.1%) |
| Dec 2021 | $203.43M(-29.5%) | $203.43M(-5.5%) |
| Sep 2021 | - | $215.28M(-3.8%) |
| Jun 2021 | - | $223.77M(-12.5%) |
| Mar 2021 | - | $255.64M(-11.4%) |
| Dec 2020 | $288.64M(+59.1%) | $288.64M(+41.3%) |
| Sep 2020 | - | $204.29M(-3.2%) |
| Jun 2020 | - | $210.97M(-6.6%) |
| Mar 2020 | - | $225.77M(+24.5%) |
| Dec 2019 | $181.38M(-5.7%) | $181.38M(+55.2%) |
| Sep 2019 | - | $116.89M(+33.8%) |
| Jun 2019 | - | $87.34M(-28.9%) |
| Mar 2019 | - | $122.78M(-36.1%) |
| Dec 2018 | $192.25M(+91.7%) | $192.25M(+55.3%) |
| Sep 2018 | - | $123.82M(+251.7%) |
| Jun 2018 | - | $35.20M(-92.1%) |
| Mar 2018 | - | $444.14M(+342.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2017 | $100.30M(+51.1%) | $100.30M(+22.4%) |
| Sep 2017 | - | $81.92M(+32.7%) |
| Jun 2017 | - | $61.74M(+3.6%) |
| Mar 2017 | - | $59.60M(-10.2%) |
| Dec 2016 | $66.40M(+98.2%) | $66.40M(+22.3%) |
| Sep 2016 | - | $54.30M(+50.2%) |
| Jun 2016 | - | $36.16M(+82.3%) |
| Mar 2016 | - | $19.83M(-40.8%) |
| Dec 2015 | $33.50M(-8.0%) | $33.50M(+27.4%) |
| Sep 2015 | - | $26.29M(-20.6%) |
| Jun 2015 | - | $33.11M(+28.3%) |
| Mar 2015 | - | $25.81M(-29.1%) |
| Dec 2014 | $36.40M(+10.4%) | $36.40M(-3.7%) |
| Sep 2014 | - | $37.78M(+216.0%) |
| Jun 2014 | - | $11.96M(-2.4%) |
| Mar 2014 | - | $12.25M(-62.9%) |
| Dec 2013 | $32.98M(-18.2%) | $32.98M(+43.7%) |
| Sep 2013 | - | $22.95M(-32.3%) |
| Jun 2013 | - | $33.91M(+79.3%) |
| Mar 2013 | - | $18.91M(-53.1%) |
| Dec 2012 | $40.30M(-17.0%) | $40.30M(+72.1%) |
| Sep 2012 | - | $23.41M(-50.4%) |
| Jun 2012 | - | $47.24M(+197.8%) |
| Mar 2012 | - | $15.87M(-67.3%) |
| Dec 2011 | $48.54M(+104.5%) | $48.54M(+194.5%) |
| Sep 2011 | - | $16.48M(-30.6%) |
| Dec 2010 | $23.74M(-24.4%) | $23.74M(-6.0%) |
| Sep 2010 | - | $25.26M(-19.6%) |
| Dec 2009 | $31.41M(-40.6%) | $31.41M |
| Dec 2008 | $52.88M | - |
FAQ
- What is Supernus Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Supernus Pharmaceuticals quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
What is Supernus Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of SUPN is $69.33M
What is the all time high annual cash & cash equivalents for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual cash & cash equivalents is $288.64M
What is Supernus Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, SUPN annual cash & cash equivalents has changed by -$5.72M (-7.63%)
What is Supernus Pharmaceuticals quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of SUPN is $115.85M
What is the all time high quarterly cash & cash equivalents for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly cash & cash equivalents is $444.14M
What is Supernus Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
Over the past year, SUPN quarterly cash & cash equivalents has changed by +$52.45M (+82.72%)